Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma.

@article{Nishikawa2012PercutaneousRA,
  title={Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma.},
  author={Hiroki Nishikawa and Yukio Osaki and Eriko Iguchi and Haruhiko Takeda and Yoshiaki Ohara and Azusa Sakamoto and Keiichi Hatamaru and Sumio Saito and Akihiro Nasu and Ryuichi Kita and Tōru Kimura},
  journal={Anticancer research},
  year={2012},
  volume={32 11},
  pages={5059-65}
}
AIM To compare the overall survival (OS) in patients without recurrent hepatocellular carcinoma (HCC) after initial radiofrequency ablation (RFA) and in those with recurrence, treated with repeat-RFA. PATIENTS AND METHODS We compared OS between patients without recurrence (group A; n=150) and those with recurrence treated with repeat-RFA (group B; n=130). RESULTS One-, 3- and 5-year OS after initial RFA was 92.6%, 84.1% and 81.0%, respectively, in group A, and 99.0%, 84.1% and 61.8% in… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…